Exclusive in Lebanon · IDL Diagnostics, Sweden
UBC Rapid: bladder cancer detection from a urine sample
A quantitative point-of-care test that measures cytokeratin 8/18 fragments in urine. The result is ready during the patient's visit, read on the Omega 100 reader.
Why it matters
9thmost common cancer in the world
3–4×higher risk in men than women; smoking and industrial chemicals raise it further
70%+are non-muscle-invasive at diagnosis, but recurrence is high, so patients need regular follow-up
Cystoscopy is invasive and uncomfortable, and urine cytology often misses low-grade tumors and carcinoma in situ. UBC Rapid adds a fast, non-invasive urine marker to the work-up, at the first visit and at every follow-up.
How it works
- 1Collect a urine sample. No preparation and no invasive procedure.
- 2Run the UBC Rapid test cassette. It detects cytokeratin 8/18 fragments released by tumor cells.
- 3Read it on the Omega 100. A quantitative, reproducible result, available while the patient is still in clinic.
The evidence
88%sensitivity when UBC Rapid is combined with cytology in high-risk patients (IDL clinical evaluation).
Urology, 2024In follow-up of recurrent non-muscle-invasive bladder cancer, UBC Rapid was among the urinary markers that outperformed cytology.
Urologia Internationalis, 2023More sensitive and less time-consuming than urine cytology for high-grade urothelial carcinoma and carcinoma in situ.
UBC Rapid is an aid to diagnosis and follow-up, used alongside cystoscopy and cytology. For professional use.
Who uses it
Urology departmentsOncology centersHospital laboratoriesPrivate urology clinics
Bring UBC Rapid to your department
We install the Omega 100 reader, train your team and supply kits of 20 tests.